-
Patent Agency Ranking
公开(公告)号：KR1020130020085A
公开(公告)日：2013-02-27
申请号：KR1020110082481
申请日：2011-08-18
Applicant: 성균관대학교산학협력단 , 대한민국 (식품의약품안전처장)
IPC: G01N33/493 , G01N33/15 , G01N33/48
CPC classification number: G01N33/493 , G01N33/00 , G01N33/15 , G01N33/48
Abstract: PURPOSE: A method for discriminating nephrotoxicity of a drug and a method for screening a nephrotoxicity-inducing material are provided to accurately determine nephrotoxicity with high sensitivity and specificity. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring concentration 1 of acetate and dimethyl glycine contained in urine from a drug-injected individual; a step of comparing concentration 1 with concentration 2 of acetate and dimethyl glycine contained in urine from a control group; and a step of determining whether concentration 1 is significantly changed. A method for screening a nephrotoxicity-inducing material comprises: a step of injecting a test composition or a test compound into an individual as an experimental group; a step of measuring and comparing the concentration of acetate and dimethyl glycine contained in urine from a control group; and a step of selecting a test composition or test compound which significantly changes the concentration of acetate and dimethyl glycine compared with the control group.
Abstract translation: 目的：提供用于鉴别药物肾毒性的方法和筛选肾毒性诱导物质的方法，以高灵敏度和特异性精确测定肾毒性。 构成：测定药物的肾毒性的方法，其特征在于，测定来自药物注射个体的尿液中所含的乙酸盐和二甲基甘氨酸的浓度1的步骤。 从对照组中比较浓缩物1与尿液中所含的乙酸盐和二甲基甘氨酸的浓度2的步骤; 以及确定浓度1是否显着改变的步骤。 筛选肾毒性诱导材料的方法包括：将试验组合物或试验化合物作为实验组注入个体的步骤; 测量和比较对照组尿液中所含的乙酸盐和二甲基甘氨酸的浓度的步骤; 以及与对照组相比，选择显着改变乙酸盐和二甲基甘氨酸浓度的测试组合物或测试化合物的步骤。
-
公开(公告)号：KR1020130020086A
公开(公告)日：2013-02-27
申请号：KR1020110082482
申请日：2011-08-18
Applicant: 성균관대학교산학협력단 , 대한민국 (식품의약품안전처장)
IPC: G01N33/493 , G01N33/15 , G01N33/48
CPC classification number: G01N33/493 , G01N33/00 , G01N33/15 , G01N33/48
Abstract: PURPOSE: A method for determining nephrotoxicity using concentration change of acetate and trimethylamine-N-oxide(TMAO) contained in urine is provided to ensure high sensitivity and specificity. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring the concentration 1 of acetate and trimethylamine-N-oxide(TMAO) contained in urine which is injected with a drug; a step of comparing the concentration 2 of acetate and TMAO contained in urine from a control group; and a step of determining whether the concentration 1 is significantly changed.
Abstract translation: 目的：提供使用尿中含有的乙酸盐和三甲胺-N-氧化物（TMAO）的浓度变化来确定肾毒性的方法，以确保高灵敏度和特异性。 构成：测定药物的肾毒性的方法，包括：测定注射有药物的尿中含有的乙酸盐和三甲胺-N-氧化物（TMAO）的浓度1的步骤; 从对照组中比较尿中含有的乙酸盐浓度2和TMAO的步骤; 以及确定浓度1是否显着变化的步骤。
-
公开(公告)号：KR1020130020084A
公开(公告)日：2013-02-27
申请号：KR1020110082480
申请日：2011-08-18
Applicant: 성균관대학교산학협력단 , 대한민국 (식품의약품안전처장)
IPC: G01N33/493 , G01N33/15 , G01N33/48
CPC classification number: G01N33/493 , G01N33/00 , G01N33/15 , G01N33/48
Abstract: PURPOSE: A method for determining nephrotoxicity of a drug using concentration change of acetate and citrate contained in urine is provided to ensure high sensitivity and specificity and to develop a safety novel drug. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring the concentration 1 of acetate and citrate contained in urine from a drug-injected individual; a step of comparing the concentration 1 with the concentration 2 of acetate and citrate contained in urine from a control group; and a step of determining whether the concentration 1 is significantly changed. The individual is a mammal exclusive of humans.
Abstract translation: 目的：提供使用尿中含有的醋酸盐和柠檬酸盐浓度变化来确定药物的肾毒性的方法，以确保高灵敏度和特异性，并开发出安全新型药物。 构成：测定药物的肾毒性的方法，包括：测定来自药物注射个体的尿液中所含的乙酸盐和柠檬酸盐的浓度1的步骤; 比较浓度1与来自对照组的尿液中所含的乙酸盐和柠檬酸的浓度2的步骤; 以及确定浓度1是否显着变化的步骤。 个人是不属于人类的哺乳动物。
-
公开(公告)号：KR101131597B1
公开(公告)日：2012-05-17
申请号：KR1020090019671
申请日：2009-03-09
Applicant: 대한민국 (식품의약품안전처장) , 한국생명공학연구원 , 서울대학교산학협력단
IPC: G01N33/15 , C12N15/33 , A01K67/027
Abstract: 본 발명은 사람의 B형 간염바이러스 X유전자로 형질전환된 동종접합 마우스에 목적하는 약물을 투여하고, 시험약물을 투여하지 않은 마우스와 비교하여 시험약물의 발암성 여부를 확인하는 단계를 포함하는 발암성을 나타내는 약물을 판별하는 방법에 관한 것이다. 본 발명의 발암성을 나타내는 약물을 판별하는 방법은 (i) 사람의 B형 간염 바이러스 X 유전자로 형질전환된 동형접합(homozygous) HBx
Ob 마우스(KCTC 11068BP)에 시험약물을 투여하고 사육하는 단계; 및, (ii) 상기 마우스로부터 간을 적출하여, 적출된 간 조직의 병변을 관찰한 다음, 시험약물을 투여하지 않은 HBx
Ob 마우스의 그것들과 비교하여, 시험약물의 발암성 여부를 확인하는 단계를 포함한다. 본 발명의 방법을 이용하면, 목적하는 약물의 간 발암성을 단시간에 효과적으로 예측하여, 신약의 발암성 시험에 소요되는 비용과 시간을 절감할 수 있으므로, 보다 경제적이고 효과적인 의약의 개발에 널리 이바지 할 수 있을 것이다.
B형 간염 바이러스 X 유전자, 시험약물, 발암성-
公开(公告)号：KR1020100101272A
公开(公告)日：2010-09-17
申请号：KR1020090019671
申请日：2009-03-09
Applicant: 대한민국 (식품의약품안전처장) , 한국생명공학연구원 , 서울대학교산학협력단
IPC: G01N33/15 , C12N15/33 , A01K67/027
Abstract: PURPOSE: A method for determining a drug with carcinogenicity is provided to effectively predict carcinogenicity in a short time and to reduce time and cost for testing carcinogenicity of a novel drug. CONSTITUTION: A method for determining a drug with carcinogenicity comprises: a step of administering test drug to homogygous HBx^Ob mouse(KCTC 11068BP) which is transformed with a hepatitis virus X gene and raising; a step of extracting the liver from the mouse and observing lesion of extracted liver; a step of comparing the liver with a liver of HBx^Ob mouse in which test drug is not administered; a step of checking the carcinogenicity of the test drug. The HBx^Ob mouse is raised at least 26 weeks. The lesion of the liver is hepatic alternative foci. The hepatic alternative foci are basophilic foci, eosinophilic foci, clear cell foci, amphophilic foci, vacuolated foci or mixed foci.
Abstract translation: 目的：提供一种确定具有致癌性的药物的方法，以在短时间内有效预测致癌性，并减少测试新药的致癌性的时间和成本。 构成：用于确定具有致癌性的药物的方法包括：将试验药物施用于用肝炎病毒X基因转化并升高的同型HBx ^ Ob小鼠（KCTC 11068BP）的步骤; 从小鼠中提取肝脏并观察肝脏病变的一个步骤; 将肝脏与未施用测试药物的HBx ^ Ob小鼠的肝脏进行比较的步骤; 检查试验药物的致癌性的步骤。 HBx ^ Ob小鼠至少培养26周。 肝脏的病变是肝替代灶。 肝替代灶是嗜碱性灶，嗜酸粒细胞病灶，透明细胞病灶，两性灶，空泡化灶或混合灶。
-
-
-
-
Search Results
5
records
(took 0.024 seconds)
